Y Intercept Hong Kong Ltd Acquires Shares of 3,893 Masimo Co. (NASDAQ:MASI)

Y Intercept Hong Kong Ltd acquired a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,893 shares of the medical equipment provider's stock, valued at approximately $519,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Edgestream Partners L.P. bought a new position in shares of Masimo during the 2nd quarter worth $645,000. Simplify Asset Management Inc. lifted its stake in Masimo by 120.4% in the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider's stock worth $2,729,000 after acquiring an additional 11,838 shares during the period. ING Groep NV increased its position in Masimo by 143.3% during the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider's stock valued at $32,119,000 after purchasing an additional 141,900 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after purchasing an additional 262,370 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider's stock worth $153,314,000 after purchasing an additional 360,497 shares during the period. 85.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. BTIG Research boosted their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Piper Sandler raised their price objective on Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Raymond James raised shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price objective on the stock in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus reissued a "buy" rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $170.67.

Masimo Stock Performance

Shares of NASDAQ:MASI traded up $1.12 on Monday, hitting $177.26. 691,495 shares of the company were exchanged, compared to its average volume of 664,973. The firm has a market capitalization of $9.49 billion, a P/E ratio of 122.68 and a beta of 1.01. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $180.97. The stock's 50 day moving average price is $157.26 and its 200 day moving average price is $133.23.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm's revenue was up 5.4% compared to the same quarter last year. Sell-side analysts predict that Masimo Co. will post 4.03 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.